Tuesday, July 23, 2024

Juvéderm Voluma XC Feasible for Correcting Infraorbital Hollows

High patient satisfaction and acceptable safety profile based on experience of 101 patients

MONDAY, April 9, 2018 (HealthDay News) — Juvéderm Voluma XC is feasible and seems safe for correcting infraorbital hollows, according to a study published online April 5 in JAMA Facial Plastic Surgery.

Michael B. Hall, M.D., from the Buckingham Center for Facial Plastic Surgery in Austin, Texas, and colleagues conducted a retrospective observational study involving patients aged 21 to 85 years who underwent Juvéderm Voluma XC treatment to correct infraorbital hollows as a singular intervention. The intervention was an injection of Juvéderm Voluma XC to the tear trough, nasojugal fold, and/or palpebromalar groove. In total, 202 eyes in 101 patients were treated and followed up for a mean of 12 months.

The researchers found that the average initial treatment volume was 1 mL, with 18 patients requiring additional treatment within three months. The average time to additional treatment was 35.7 days. Adverse effects included bruising, contour irregularities, swelling, and Tyndall effect, and these occurred in 10, 2, 3, and 1 percent of patients, respectively. Three patients required hyaluronidase. After treatment 41 percent of patients completed the FACE-Q Satisfaction With Eyes survey, and 42 percent of patients completed the FACE-Q Satisfaction With Decision survey. Based on both FACE-Q scores, the overall mean patient satisfaction was 71.1 and 65.6 percent, respectively.

“Juvéderm Voluma XC has a high patient satisfaction profile and an acceptable safety profile for the correction of infraorbital hollowing,” the authors write.

Abstract/Full Text

Copyright © 2018 HealthDay. All rights reserved.

the authorHealthDay.com